This week’s health insurance industry policy conference provides an opportunity to gain insights on the prospects of drug pricing reforms following a week that highlighted the difficulty Democrats likely would face if they try to pass a second budget reconciliation bill later this year that many believe is the most likely vehicle for major drug pricing legislation. Insurance and drug industries mostly fought to a draw during the Trump administration, so the focus shifts to the new dynamics of a...